BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Callan Family Office LLC

Callan Family Office LLC decreased its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 37.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 41,891 shares of the biotechnology company’s stock after selling 25,147 shares during the quarter. Callan Family Office LLC’s holdings in BioMarin Pharmaceutical were worth $2,269,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Jones Financial Companies Lllp raised its position in BioMarin Pharmaceutical by 88.1% in the third quarter. Jones Financial Companies Lllp now owns 1,401 shares of the biotechnology company’s stock valued at $75,000 after purchasing an additional 656 shares during the period. Mediolanum International Funds Ltd grew its position in shares of BioMarin Pharmaceutical by 56.2% during the third quarter. Mediolanum International Funds Ltd now owns 137,675 shares of the biotechnology company’s stock worth $7,437,000 after buying an additional 49,534 shares in the last quarter. Transcend Capital Advisors LLC raised its holdings in shares of BioMarin Pharmaceutical by 22.8% in the 3rd quarter. Transcend Capital Advisors LLC now owns 4,827 shares of the biotechnology company’s stock valued at $261,000 after purchasing an additional 895 shares in the last quarter. National Pension Service increased its holdings in shares of BioMarin Pharmaceutical by 47.1% in the 3rd quarter. National Pension Service now owns 20,412 shares of the biotechnology company’s stock valued at $1,106,000 after acquiring an additional 6,534 shares during the last quarter. Finally, Arizona State Retirement System boosted its holdings in shares of BioMarin Pharmaceutical by 1.3% in the 3rd quarter. Arizona State Retirement System now owns 56,734 shares of the biotechnology company’s stock valued at $3,073,000 after buying an additional 716 shares in the last quarter. Hedge funds and other institutional investors own 98.71% of the company’s stock.

Analysts Set New Price Targets

BMRN has been the topic of a number of research reports. Canaccord Genuity Group upgraded shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and raised their target price for the stock from $84.00 to $98.00 in a research report on Tuesday, January 20th. Weiss Ratings reissued a “sell (d)” rating on shares of BioMarin Pharmaceutical in a research note on Monday, December 29th. Tudor Pickering set a $88.00 price target on shares of BioMarin Pharmaceutical in a research report on Monday, November 3rd. Morgan Stanley lowered their price target on shares of BioMarin Pharmaceutical from $104.00 to $98.00 and set an “overweight” rating for the company in a report on Tuesday, October 28th. Finally, Wolfe Research reiterated an “outperform” rating on shares of BioMarin Pharmaceutical in a report on Tuesday, October 28th. Seventeen research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $90.04.

BioMarin Pharmaceutical Stock Up 0.0%

BMRN stock opened at $57.62 on Thursday. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.83 and a quick ratio of 3.10. The firm has a fifty day moving average price of $56.63 and a two-hundred day moving average price of $55.95. BioMarin Pharmaceutical Inc. has a 1-year low of $50.76 and a 1-year high of $73.51. The firm has a market cap of $11.07 billion, a price-to-earnings ratio of 21.66, a PEG ratio of 0.63 and a beta of 0.26.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.